Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROTO

Financiado

PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATI...

PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIENT OUTCOMES Osteoarthritis (OA) is the most common form of arthritis worldwide. Chronic low-grade inflammation in the articular environment causes cartilage degeneration at an early disease stage, resulting in chronic pain, disability and los... ver más

31/12/2027

CHARITE UNIVERSIT...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-17

HORIZON-HLTH-2022-STAYHLTH-02-01: Personalised blueprint of chronic i... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

11 Participantes

CHARITE UNIVERSITAETSMEDIZI...

4.32M€ | Lider

QUEENSLAND UNIVERSITY OF TEC...

N.D. | Participante

UOULU

527.50K€ | Participante

TAT

240.68K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2022-133753-I00 BOTS EN ARTICULACIONES 150K€ Cerrado

PID2019-110709RB-I00 DESARROLLO DE MICROCAPSULAS BIOADHESIVAS PARA NUEVOS TRATAMI... 254K€ Cerrado

EIN2019-103177 INNOVACION EN INGENIERIA REGENERATIVA PARA LA INTERVENCION T... 16K€ Cerrado

SINPAIN A game changer for the treatment of osteoarthritis: a cost e... 5M€ Cerrado

PTQ-08-03-08731 I+D DE LA TECNOLOGÍA PRGF PARA SU APLICACIÓN EN PATOLOGÍAS A... 55K€ Cerrado

PTQ-08-03-08881 I+D DE LA TECNOLOGÍA PRGF PARA PATOLOGÍAS ARTICULARES: ARTRO... 76K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2022-11-17
Fecha Fin: 2027-12-31

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Descripción del proyecto Osteoarthritis (OA) is the most common form of arthritis worldwide. Chronic low-grade inflammation in the articular environment causes cartilage degeneration at an early disease stage, resulting in chronic pain, disability and loss of independence due to progressive joint destruction. To date, no treatment is available to sustainably combat low-grade inflammation in early-stage OA patients. Biomechanical causes for intra-articular inflammation and OA development have been detected in specific patient groups. The PROTO consortium strives to implement new evidence- and patient-centred treatment strategies for early- and pre-disease stages. For the first time, early-stage knee OA patients will be treated with local PLX-PAD injections, a novel allogeneic cell therapy product with distinct anti-inflammatory capacities that may halt or revert disease progression. Secondly, patients recovering from anterior cruciate ligament reconstructions with pathological gait patterns leading to knee OA, will be treated with a personalized sensor-based digital training intervention. We intend to prevent health to disease transition by restoring physiological movement and reducing joint inflammation. To assess treatment success in early- and pre-stage OA, PROTO gathers scientific and clinical specialists who have genuinely shaped clinical, radiological and biomarker outcome parameters for OA in recent years. This will be the first time that these renowned experts join forces to analyze, stratify and compare fundamentally novel disease modifying treatment strategies for OA in one consortium. PROTO was developed with the help of patient organizations, industry partners and research societies. Restoring physiological joint homeostasis at an early disease stage may be the key to understanding health to disease progression in OA. Targeting this ‘window of opportunity’ will fundamentally change the way OA is treated today and in the future.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores